Regulation & Compliance

A new partnership aims to create a one-stop shop for crypto firms, combining regulatory licensing with institutional-grade digital asset custody.

After 16 years, Chief Legal Officer Anthony Green announces his retirement, leaving a void at the top and questions about Annaly's future governance.

Kite Realty Group declared a special dividend for shareholders. We dig into whether this signals a healthy retail market or is simply a savvy tax strategy.

A private tender offer values diagnostics firm PathoCare at $1.75B. Can its AI-powered, non-invasive technology justify the price and transform medicine?

The National Police Federation slams a report backing a provincial police force, citing high costs, low public support, and broken promises.

A new multiyear pact between Envision Healthcare and BCBS of Arizona ends uncertainty, ensuring stable in-network access to critical medical services.

A historic $50M donation from Tom Golisano propels Arkansas Children's into a national alliance, tackling the state's critical child health crisis.

With promising survival data and a pivotal Phase 3 trial underway, Imunon's localized immunotherapy could finally change the game for ovarian cancer.

VideoAmp appoints President Tony Fagan as its next CEO, signaling a major strategic shift toward 'agentic AI' to redefine advertising measurement.

Capstone Accounting's acquisition of North Star signals a major shift in Washington's local market, reflecting a national trend of industry consolidation.

Vasco Electronics unveils AI that translates presentations in real-time and mimics vocal emotion, pushing the boundaries of multilingual interaction.

With industry veteran Kevin Muskat at the helm, Leon Capital Group's new advisory practice promises M&A guidance free from audit firm conflicts.

Mount Logan Capital offers shareholders a 14% premium in a $15M tender offer, signaling confidence despite mixed financials and a complex market identity.

A new multi-million dollar partnership highlights how AI and automation are radically transforming the insurance industry's outdated payment systems.

Branded Legacy just wiped out $1M in legacy debt. The move is part of a radical overhaul by new management aimed at rebuilding investor confidence.

Genmab discontinues its 'encouraging' lung cancer drug, acasunlimab, in a bold strategic pivot to accelerate its most promising late-stage assets.

A chiropractor with millions of followers claims he can reverse dementia. As science eyes a breakthrough, we examine the hope, the hype, and the business.

With promising new drugs for obesity and liver disease, clinical-stage MetaVia steps into the spotlight at a key industry conference, facing giants and high hopes.

With a promising schizophrenia drug stalled by FDA requirements and finances tight, Reviva Pharmaceuticals' upcoming presentation is more than just a talk.

Chinese firm launches durable centrifuges for sub-zero climates and announces a major localization strategy to capture a multi-billion dollar market.